Albany Molecular Research Inc. (AMRI) Sees Strong Trading Volume
Albany Molecular Research Inc. (NASDAQ:AMRI) saw unusually-high trading volume on Friday . Approximately 1,167,634 shares were traded during mid-day trading, an increase of 203% from the previous session’s volume of 385,752 shares.The stock last traded at $14.44 and had previously closed at $14.32.
Separately, Morgan Stanley reissued a “buy” rating on shares of Albany Molecular Research in a report on Sunday, May 8th.
The firm’s market capitalization is $498.24 million. The firm’s 50-day moving average price is $13.99 and its 200-day moving average price is $14.84.
Albany Molecular Research (NASDAQ:AMRI) last issued its earnings results on Tuesday, May 10th. The company reported $0.07 EPS for the quarter, missing the Zacks’ consensus estimate of $0.21 by $0.14. The company earned $102.80 million during the quarter, compared to analysts’ expectations of $107.20 million. On average, equities research analysts predict that Albany Molecular Research Inc. will post $1.05 EPS for the current year.
In related news, COO George Svokos purchased 12,500 shares of the firm’s stock in a transaction on Friday, May 13th. The stock was bought at an average cost of $12.82 per share, with a total value of $160,250.00. Following the completion of the acquisition, the chief operating officer now owns 108,685 shares of the company’s stock, valued at approximately $1,393,341.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kevin Oconnor sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total value of $72,050.00. Following the completion of the transaction, the director now directly owns 52,955 shares of the company’s stock, valued at $763,081.55. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Albany Molecular Research stock. Bank of Montreal Can increased its position in shares of Albany Molecular Research Inc. (NASDAQ:AMRI) by 5.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 878,664 shares of the company’s stock after buying an additional 48,436 shares during the period. Bank of Montreal Can owned about 2.55% of Albany Molecular Research worth $17,442,000 at the end of the most recent reporting period.
Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.